These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 29973279)
1. The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome. Davidson YS; Robinson A; Prasher VP; Mann DMA Acta Neuropathol Commun; 2018 Jul; 6(1):56. PubMed ID: 29973279 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643 [TBL] [Abstract][Full Text] [Related]
3. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Stoltzner SE; Grenfell TJ; Mori C; Wisniewski KE; Wisniewski TM; Selkoe DJ; Lemere CA Am J Pathol; 2000 Feb; 156(2):489-99. PubMed ID: 10666378 [TBL] [Abstract][Full Text] [Related]
4. Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer's Disease. Helman AM; Siever M; McCarty KL; Lott IT; Doran E; Abner EL; Schmitt FA; Head E J Alzheimers Dis; 2019; 67(1):103-112. PubMed ID: 30452414 [TBL] [Abstract][Full Text] [Related]
5. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. Snow AD; Mar H; Nochlin D; Sekiguchi RT; Kimata K; Koike Y; Wight TN Am J Pathol; 1990 Nov; 137(5):1253-70. PubMed ID: 2146882 [TBL] [Abstract][Full Text] [Related]
6. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC; J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567 [TBL] [Abstract][Full Text] [Related]
7. Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue. Lemoine L; Ledreux A; Mufson EJ; Perez SE; Simic G; Doran E; Lott I; Carroll S; Bharani K; Thomas S; Gilmore A; Hamlett ED; Nordberg A; Granholm AC Mol Neurodegener; 2020 Nov; 15(1):68. PubMed ID: 33222700 [TBL] [Abstract][Full Text] [Related]
8. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Perez-Nievas BG; Stein TD; Tai HC; Dols-Icardo O; Scotton TC; Barroeta-Espar I; Fernandez-Carballo L; de Munain EL; Perez J; Marquie M; Serrano-Pozo A; Frosch MP; Lowe V; Parisi JE; Petersen RC; Ikonomovic MD; López OL; Klunk W; Hyman BT; Gómez-Isla T Brain; 2013 Aug; 136(Pt 8):2510-26. PubMed ID: 23824488 [TBL] [Abstract][Full Text] [Related]
9. Precortical Phase of Alzheimer's Disease (AD)-Related Tau Cytoskeletal Pathology. Stratmann K; Heinsen H; Korf HW; Del Turco D; Ghebremedhin E; Seidel K; Bouzrou M; Grinberg LT; Bohl J; Wharton SB; den Dunnen W; Rüb U Brain Pathol; 2016 May; 26(3):371-86. PubMed ID: 26193084 [TBL] [Abstract][Full Text] [Related]
10. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease. Mendonça CF; Kuras M; Nogueira FCS; Plá I; Hortobágyi T; Csiba L; Palkovits M; Renner É; Döme P; Marko-Varga G; Domont GB; Rezeli M Neurobiol Dis; 2019 Oct; 130():104509. PubMed ID: 31207390 [TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Serrano-Pozo A; William CM; Ferrer I; Uro-Coste E; Delisle MB; Maurage CA; Hock C; Nitsch RM; Masliah E; Growdon JH; Frosch MP; Hyman BT Brain; 2010 May; 133(Pt 5):1312-27. PubMed ID: 20360050 [TBL] [Abstract][Full Text] [Related]
12. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Lemere CA; Blusztajn JK; Yamaguchi H; Wisniewski T; Saido TC; Selkoe DJ Neurobiol Dis; 1996 Feb; 3(1):16-32. PubMed ID: 9173910 [TBL] [Abstract][Full Text] [Related]
15. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234 [TBL] [Abstract][Full Text] [Related]
17. Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele. Vidal R; Calero M; Piccardo P; Farlow MR; Unverzagt FW; Méndez E; Jiménez-Huete A; Beavis R; Gallo G; Gomez-Tortosa E; Ghiso J; Hyman BT; Frangione B; Ghetti B Acta Neuropathol; 2000 Jul; 100(1):1-12. PubMed ID: 10912914 [TBL] [Abstract][Full Text] [Related]
18. Unique Pathology in the Locus Coeruleus of Individuals with Down Syndrome. Saternos H; Hamlett ED; Guzman S; Head E; Granholm AC; Ledreux A J Alzheimers Dis; 2024; 101(2):541-561. PubMed ID: 39213062 [TBL] [Abstract][Full Text] [Related]
19. Changes in glial cell phenotypes precede overt neurofibrillary tangle formation, correlate with markers of cortical cell damage, and predict cognitive status of individuals at Braak III-IV stages. Taddei RN; Sanchez-Mico MV; Bonnar O; Connors T; Gaona A; Denbow D; Frosch MP; Gómez-Isla T Acta Neuropathol Commun; 2022 May; 10(1):72. PubMed ID: 35534858 [TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. Moncaster JA; Pineda R; Moir RD; Lu S; Burton MA; Ghosh JG; Ericsson M; Soscia SJ; Mocofanescu A; Folkerth RD; Robb RM; Kuszak JR; Clark JI; Tanzi RE; Hunter DG; Goldstein LE PLoS One; 2010 May; 5(5):e10659. PubMed ID: 20502642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]